As a major innovative hub for (bio)pharma innovation, Ireland should be a place where innovative medicines are adopted quickly within the local healthcare system. IPHA director Oliver O’Connor explains the significance of the new 2016 IPHA agreement in contributing to a sustainable Irish healthcare budget and the delivery of innovative medicines to patients, highlights further room for progress for Ireland in terms of innovation access, and outlines IPHA’s main priorities for the next few years.
The big news for IPHA is the new Agreement, concluded on 20 July 2016, which saw a number of new initiatives projected to save Ireland EUR 785 million over the next four years. Can you provide an overview of this agreement?
Finding ways to support the early adoption of innovative medicines within a strict and sustainable budgetary framework has been a challenge here.
